Jubilant Draximage Radiopharmacies, Inc.

Jubilant Draximage Radiopharmacies, Inc., doing business as Jubilant Radiopharma, manufactures and distributes radiopharmaceuticals and nuclear medicine products to the Department of Veterans Affairs and the Department of Defense as a prime contractor, operating as a for-profit small disadvantaged business subsidiary of Jubilant Life Sciences Limited headquartered in Norcross, Georgia.

Jubilant Radiopharma's capability portfolio centers on manufacturing, formulation, and delivery of specialized medical isotopes and diagnostic imaging agents for nuclear medicine procedures. The vendor supplies technetium-99m, gallium-68 Dotatate, iodine-123, iodine-131, fluorine-18 fluorodeoxyglucose, gallium-67 citrate, indium-111 pentetreotide, and related radiopharmaceuticals to support positron emission tomography scans, cardiac imaging, cancer treatment diagnostics, and therapeutic nuclear medicine procedures. Representative recent awards include a $1.49 million delivery order from Veterans Integrated Service Network 8 in January 2023 for radiopharmaceutical supply, a $1.12 million blanket purchase agreement call from VISN 16 in April 2023 for radiopharmaceutical supplies to Mississippi and Florida VA facilities, and a $3.06 million indefinite-delivery contract from VISN 4 in August 2024 for radiopharmaceuticals to Lebanon VA Medical Center. The vendor also holds a $924.5 thousand indefinite-delivery contract from the Defense Health Agency awarded January 2026 for radiopharmaceuticals to Madigan Army Medical Center.

Jubilant Radiopharma's customer base concentrates heavily within the VA system. The top five customer VISNs account for 55 percent of awards by count, with VISN 8 anchoring the dollars: VISN 8 holds 10 awards valued at $44.9 million combined potential value; VISN 4 holds 11 awards at $6.5 million; VISN 22 holds 10 awards at $5 million; VISN 23 holds 4 awards at $4.6 million; and VISN 10 holds 14 awards at $4.2 million. Across 17 distinct customer agencies served, 73 percent of combined potential value flows to these five VISNs. The vendor has entered a recent engagement with the Defense Health Agency for Madigan Army Medical Center, signaling expansion beyond VA.

Jubilant Radiopharma manages a portfolio of 19 single-award indefinite-delivery contracts and blanket purchase agreements across multiple VISNs, with ceiling values ranging from $220 thousand to $39.8 million. The largest vehicle, VISN 8's multiple-award indefinite-delivery contract, carries a $39.8 million ceiling through September 2027 and has generated eight delivery orders totaling $5 million in combined potential value against it. VISN 4's indefinite-delivery contract for Lebanon VA Medical Center carries a $3.06 million ceiling through July 2029; VISN 23's radiopharmaceutical agents contract for Minneapolis VA Medical Center carries a $3.34 million ceiling through September 2028; and VISN 15's contract for Kansas City VA Medical Center carries a $2.29 million ceiling through January 2030. Other significant vehicles include VISN 17's indefinite-delivery contract at $3.02 million, VISN 6's at $2.60 million, and VISN 22's Loma Linda Healthcare System contract at $2.41 million. These vehicles structure firm-fixed-price delivery orders, typically with base periods of one year and multiple option years, enabling the VA to procure radiopharmaceuticals on an as-needed basis.

Activity has grown from 6 awards in 2022 to 25 awards in 2025, with 14 awards in the current year (through August 2026). Nineteen awards carrying combined potential value of $6.8 million reach ultimate completion within the next twenty-four months, creating recompete exposure for multiple VISN contracts. The vendor competes exclusively on full-and-open, non-set-aside basis across its portfolio, with two exceptions: one total small business set-aside delivery order from VISN 10 in December 2023 for $420 thousand (nuclear medicine radiopharmaceuticals) and another total small business order from VISN 10 in December 2024 for $75 thousand. Across 92 prime awards, Jubilant Radiopharma operates as the sole contractor with no subcontractor footprint in the source data. All work is performed at the vendor's manufacturing and distribution facility in Norcross, Georgia or at subordinate VA locations. The vendor's federal contracting activity demonstrates the VA's established confidence in its ability to meet stringent requirements for Nuclear Regulatory Commission licensing, rapid delivery (including emergency orders within 45 minutes to two hours), quality control testing, hazardous materials compliance, and regulatory adherence across distributed VA medical facility networks.